# Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

> **NCT04519983** · PHASE2 · UNKNOWN · sponsor: **Shanghai Cancer Hospital, China** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer Stage IV

## Interventions

- **DRUG:** Aumolertinib Oral Tablet

## Key facts

- **NCT ID:** NCT04519983
- **Lead sponsor:** Shanghai Cancer Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519983, "Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04519983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*